Skip to content

Study · Randomized controlled trial · n = 53 · 2022

3 results

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

Lepage C, Phelip JM, Lievre A, Le-Malicot K, Dahan L, Tougeron D, Toumpanakis C, Di-Fiore F, Lombard-Bohas C, Borbath I, Coriat R, Lecomte T and 7 more

Show all authors

Guimbaud R, Petorin C, Legoux JL, Michel P, Scoazec JY, Smith D, Walter T

European journal of cancer (Oxford, England : 1990)7 Sept 2022Cited by 18 (Europe PMC)

PMID36087395 (opens in a new tab)DOI10.1016/j.ejca.2022.07.033 (opens in a new tab)PepBankPUB-36087395
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In aggressive DP-NET, progression-free survival at 6 months was 73.1% with lanreotide versus 54.2% with placebo.

    In plain wordsIn aggressive DP-NET, 6-month progression-free survival was 73.1% with lanreotide versus 54.2% with placebo.

    Peptide
    Lanreotide
    Outcome
    IncreaseProgression-free survival at 6 months
    Study

    n = 53

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 days · until progression or toxicityAs given in this study (human).

    Measurements

    PFS at 6 months
    73.1%
    lanreotide
    90% CI of PFS at 6 months
    55.3 to 86.6%
    lanreotide
    PFS at 6 months
    54.2%
    placebo
    90% CI of PFS at 6 months
    35.8 to 71.8%
    placebo

    Source sentences

    Summary
    PFS at 6 months was 73.1% (90% CI: 55.3; 86.6) in LAN versus 54.2% (90% CI: 35.8; 71.8) in PBO.
    1 context sentence
    Summary · context
    This academic randomised, double-blind, placebo-controlled phase II study aims to evaluate lanreotide autogel 120 mg (LAN) as maintenance treatment after at least 2 months of first-line treatment (L1) in aggressive G1-G2 DP-NET. Patients were randomly assigned in a 1:1 ratio to receive LAN or placeb…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In aggressive DP-NET, median progression-free survival was 19.4 months with lanreotide versus 7.6 months with placebo.

    In plain wordsMedian progression-free survival was 19.4 months with lanreotide versus 7.6 months with placebo.

    Peptide
    Lanreotide
    Outcome
    IncreaseMedian progression-free survival
    Study

    n = 53

    Comparator
    placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 days · until progression or toxicityAs given in this study (human).

    Measurements

    Median PFS
    19.4 months
    lanreotide
    95% CI of median PFS
    7.6 to 32.6 months
    lanreotide
    Median PFS
    7.6 months
    placebo
    95% CI of median PFS
    3 to 9 months
    placebo

    Source sentences

    Summary
    Median PFS was 19.4 months (95% CI: 7.6; 32.6) and 7.6 months (95% CI: 3.0; 9.0), respectively.
    1 context sentence
    Summary · context
    This academic randomised, double-blind, placebo-controlled phase II study aims to evaluate lanreotide autogel 120 mg (LAN) as maintenance treatment after at least 2 months of first-line treatment (L1) in aggressive G1-G2 DP-NET. Patients were randomly assigned in a 1:1 ratio to receive LAN or placeb…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In aggressive DP-NET, median overall survival was not reached with lanreotide and was 41.9 months with placebo.

    In plain wordsMedian survival was not reached with lanreotide and was 41.9 months with placebo.

    Peptide
    Lanreotide
    Outcome
    Direction not reportedMedian overall survival
    Study

    n = 53

    Comparator
    placebo
    Outcome group
    Mortality · Cancer
    Studied dose
    120 mg every 28 days · until progression or toxicityAs given in this study (human).

    Measurements

    Median overall survival
    41.9 months
    placebo

    Source sentences

    Summary
    Median overall survival was 41.9 months in PBO and was not reached in LAN.
    1 context sentence
    Summary · context
    This academic randomised, double-blind, placebo-controlled phase II study aims to evaluate lanreotide autogel 120 mg (LAN) as maintenance treatment after at least 2 months of first-line treatment (L1) in aggressive G1-G2 DP-NET. Patients were randomly assigned in a 1:1 ratio to receive LAN or placeb…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2/3Results postedNCT02288377

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)

Federation Francophone de Cancerologie Digestiven = 53Jan 2015 to Jan 2020

Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours

Trial pageClinicalTrials.govUpdated 18 Jan 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.